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In several species, a family of nuclear receptors, the peroxisome proliferator-activated receptors (PPARs) composed of three iso-
types, is expressed in somatic cells and germ cells of the ovary as well as the testis. Invalidation of these receptors in mice or
stimulation of these receptors in vivo or in vitro showed that each receptor has physiological roles in the gamete maturation or
the embryo development. In addition, synthetic PPARγ ligands are recently used to induce ovulation in women with polycystic
ovary disease. These results reveal the positive actions of PPAR in reproduction. On the other hand, xenobiotics molecules (in her-
bicides, plasticizers, or components of personal care products), capable of activating PPAR, may disrupt normal PPAR functions
in the ovary or the testis and have consequences on the quality of the gametes and the embryos. Despite the recent data obtained
on the biological actions of PPARs in reproduction, relatively little is known about PPARs in gametes and embryos. This review
summarizes the current knowledge on the expression and the function of PPARs as well as their partners, retinoid X receptors
(RXRs), in germ cells and preimplantation embryos. The eﬀects of natural and synthetic PPAR ligands will also be discussed from
the perspectives of reproductive toxicology and assisted reproductive technology.
Copyright © 2008 Jaou-Chen Huang. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Peroxisomes are organelles in eukaryotes that remove
toxic substances and break down fatty acid. Peroxisome
proliferator-activated receptor α (PPARα) was discovered
during the search for a compound that increases the prolifer-
ation of peroxisomes in mouse liver cells [1]. Subsequently,
two additional isotypes, PPARβ (also known as PPARδ) and
PPARγ, were discovered. The three PPARs are encoded by
diﬀerent genes. Variants arising from alternative splicing and
usage of diﬀerent promoters have been reported in all three
PPARs [2]. Together they form a subfamily within the steroid
receptor superfamily. To date, PPARs have been identified in
many species, including Xenopus, sea squirt, zebrafish, Aedes
aegypti (yellow fevermosquito),Anopheles gambiae (a species
complex which contains six vectors of malaria), mouse, rat,
hamster, and human (http://www.ensembl.org/index.html).
Since their discovery, a great deal has been learned about
PPARα, PPARγ, and, to a less extent, PPARβ/δ. The knowl-
edge has been applied to clinical practice: synthetic PPARα
ligands (fibrates) and PPARγ ligands (thiazolidinediones
TZD), respectively, are widely used to treat lipid and glu-
cose disorders. In contrast, the use of PPARs to enhance fer-
tility is constrained by our relative meager knowledge re-
garding PPARs and reproduction. PPARγ activators have re-
cently been used to induce ovulation in women with poly-
cystic ovary disease, a condition of ovulation dysfunction as-
sociated with insulin resistance. This review will focus on the
roles of PPARs in the development and physiology of gametes
and preimplantation embryos. Also included in the discus-
sion are potential impacts of natural or synthetic PPAR lig-
and on reproduction and the promising benefits of synthetic
PPAR ligands in enhancing the success of assisted reproduc-
tive technology.
2. PPARs AND RXRs
PPARs, similar to steroid and thyroid hormone receptors, are
ligand-activated nuclear transcription factors. Unlike steroid
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and thyroid hormone receptors, PPARs were discovered be-
fore their functions were fully understood. Over the years,
tissue distribution and synthetic ligands, which bind to spe-
cific PPAR, helped to elucidate the biological functions of
PPARs.
PPARs form heterodimers with another nuclear recep-
tor, retinoid X receptor (RXR). This interaction occurs
in the presence and absence of PPAR ligand. The PPAR-
RXR complex recruits other cofactors before binding to
PPAR responsive element (PPRE) at the promoter regions of
PPAR-responsive genes. Besides PPARs, RXR also forms het-
erodimers with other nuclear receptors. RXR has three iso-
types: RXRα, RXRβ, and RXRγ, all of which are activated
by 9-cis-retinoic acid (but not by all-trans retinoic acid) [3].
The 9-cis-retinoic acid was originally considered as the en-
dogenous ligand for RXRs in vivo; but recent reports [4, 5]
cast considerable doubt that it is the case. Although RXRs
exist as three isotypes, they do not confer diﬀerent func-
tions to PPAR-RXR complexes. The PPAR-RXR complexes
are activated by either PPAR or RXR ligand, but simulta-
neous binding by both ligands elicits more potent activities
[6]. A unique feature of PPARβ/δ, not seen in PPARα or
PPARγ, is its ability to repress the transcriptional activities of
PPARα and PPARγ. This activity is mediated by corepressors
recruited by PPARβ/δ [7].
The DNA sequence of PPRE is typically of a direct repeat
1 (DR1) nuclear receptor in that the PPRE DNA sequence
consists of two repeats of AGGTCA separated by one nu-
cleotide (AGGTCA N AGGTCA). Detailed analyses of na-
tive PPREs show that the consensus PPRE sequence is 5′-
AACTAGGNCAAAGGTCA-3′ [6]. The extended 5′ half site,
the one imperfect DR1 core, and the adenine as the spacing
nucleotide may confer additional selectivity to the binding of
PPAR-RXR complex.
3. DISTRIBUTION AND BIOLOGICAL
FUNCTIONS OF PPAR
The functions of PPARs can be extrapolated from tissue(s)
expressing the specific PPAR isotype or from the functions of
genes regulated by specific PPAR. PPARα is expressed most
abundantly in brown adipose tissue and liver, followed by
the kidney, heart, and skeletal muscle. PPARγ is mainly ex-
pressed in adipose tissue and, to a less extent, in the colon, the
immune system, and the retina. Both PPARα and PPARγ re-
sponsive genes are involved in lipid homeostasis. Therefore,
it is not surprising that the main functions of PPARα and
PPARγ are in glucose and lipid homeostasis [6, 8].
On the other hand, the ubiquitous distribution of
PPARβ/δ (although gut, kidney, and heart express higher lev-
els than other tissues) makes it diﬃcult to associate PPARβ/δ
with specific biological function [8]. The multiple functions
of PPARβ/δ are revealed by the diverse genes regulated by
PPARβ/δ, such as ILK [9], 11 ß hydroxysteroid dehydroge-
nase II [10], PTEN [9], and 14-3-3ε [11]. It is worth not-
ing that 14-3-3ε functions as a protein chaperone. There-
fore, PPARβ/δ is indirectly associated with even more diverse
range of functions. Indeed, PPARβ/δ has been implicated in
embryo implantation [12], intestinal adenoma [13], colon
cancer [14], skin wound healing [15], hair follicle develop-
ment [16], and cytoprotection [11].
4. PPAR LIGANDS
Natural and synthetic PPAR ligands relevant to this review
are listed below. More extensive lists are available in the liter-
ature [6, 17].
Unsaturated fatty acids are ligands to all PPARs,
with PPARα exhibiting the highest aﬃnity; saturated fatty
acids, on the other hand, are not eﬀective PPAR lig-
ands. Eicosanoids derived from arachidonic acid form a
unique group of fatty acids that bind to PPARs. They in-
clude leukotrienes, hydroxyeicosatetraenoic acids (HETEs)
(both are formed via the lipoxygenase pathway), and
prostaglandins (PGs) (formed via the cyclooxygenase path-
way). Leukotriene B4 and 8(S)-HETE are PPARα ligand; and
15-deoxy-Δ12, 14-PGJ2 (15d-PGJ2, a PGD2 derivative) is a
PPARγ ligand. Synthetic PPARα (fibrates) and PPARγ (TZD)
ligands are used to lower blood lipid and glucose, respec-
tively. Prostacyclin (PGI2) is a natural PPARβ/δ ligand, in-
deed the uterine PGI2 generated by cyclooxygenase-2 (COX-
2) mediates the implantation of embryos via PPARβ/δ [12].
Synthetic PGI2 analogs, such as iloprost and carbaprostacy-
clin, may function as PGI2 receptor agonists or PPARβ/δ lig-
ands. Although iloprost is used as a PGI2 receptor agonist to
treat pulmonary hypertension and peripheral vascular dis-
eases, no PGI2 analog has been used as a PPARβ/δ ligand
clinically. A recent report indicates that retinoic acid, in cells
with high fatty acid binding protein 5 to retinoic acid bind-
ing protein-II ratio, may function as a natural PPARβ/δ lig-
and [18]. This finding may have evolutional or developmen-
tal significance in germ cell maturation, gamete function, or
embryo development. PGI2 and retinoic acid may provide
functional redundancy to ensure PPARβ/δ activation or they
may compliment each other to activate PPARβ/δ in a devel-
opmental stage-dependent manner based on the ratio of the
two binding proteins.
5. PPAR LIGANDS IN THE REPRODUCTIVE TRACT
Zygotes remain in the oviduct after fertilization and develop
to morula or early blastocyst stage embryos before enter-
ing into the uterus. It is generally accepted that, compared
with cultured embryos (derived from fertilized eggs in vitro
or flushed from oviducts at earlier developmental stage), in
vivo embryos develop better and have less cell death because
oviducts protect the embryos and promote their develop-
ment [19]. The unique environment provided by the oviduct
includes oviduct-derived soluble factors and embryo-derived
autocrine factors. Both oviducts and embryos are sources of
PPAR ligand(s).
Earlier studies show that the oviduct produces abun-
dant PGE2 and PGF2α, which regulate its motility. We
serendipitously discovered that human [20] and mouse [21]
oviducts produce other eicosanoids that activate PPARs.
PGI2 (a PPARβ/δ ligand) is the most abundant product,
PGD2 (whose derivative, 15d-PGJ2, is a PPARγ ligand), and
other products derived from the lipoxygenase pathway are
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also produced in substantial amounts. PGI2 synthesis by
mouse oviducts is synchronized with estrus cycles (and, thus,
the development of preimplantation embryos). Peak PGI2
synthetic capacity coincides with the window of receptivity,
that is, between the eight-cell and morula stages [21, 22].
Recent reports indicate that human [23] and mouse [24,
25] preimplantation embryos express COX isoenzymes and
synthesize eicosanoids. PGI2 is the most abundant metabo-
lite when radio-labeled arachidonic acid is incubated with
blastocyst-stage mouse embryos. Other eicosanoids, such as
HETEs and PGD2 are also produced by mouse blastocysts
[24].
6. RXR IN GAMETES AND PREIMPLANTATION
EMBRYOS
Gametes and preimplantation embryos express RXRs.
Whereas RXRγ-null mice are normal [26], RXRα- [27] and
RXRβ-null mice [28] have distinctive phenotypes. Gene
knockout studies show that spermatogenesis requires RXRβ.
Similarly, oocyte development may be modulated by RXR,
which is expressed in both granulosa-cumulus cells and
oocytes. Finally, the quality of embryo development may be
associated with RXR expression.
6.1. RXR in gametes
RXRα and RXRβ are expressed in human cumulus granu-
losa cells [29] and bovine oocytes [30]. Although the initial
reports on RXRα [27] and RXRβ [28] null mice did not in-
clude a description of female reproduction (such as follicular
development and ovulation), the localization of RXRα and β
in the ovary supports their roles in follicular maturation and
oocyte function. RXR may regulate oocyte development di-
rectly (via modulating steroidogenesis in the granulosa cells)
or indirectly (by aﬀecting oocyte gene transcription) [31]. It
is likely that femalemice with targeted RXR deletionmay suf-
fer subfertility.
The male sterility observed in RXRβ-null mice [28] un-
derscores the essential role of RXR (and its functional part-
ner) in spermatogenesis. In mouse testes, retinoic acid recep-
tors (RARs) and RXR are expressed in well-defined cell pop-
ulations: RARα and RXRβ in Sertoli cells, RARβ, RXRα, and
RXRγ in steps 7 and 8 spermatids, and RARγ in spermato-
gonia. Mouse spermatocytes, however, do not express RARs
[32]. Although RARβ, RXRα, and RXRγ are coexpressed in
step 7 and 8 spermatids, RARβ may not functionally cou-
ple with either RXRα or RXRγ, because RARβ-, RXRγ-, and
RARβ/RXRγ-null mice do not display reproductive defects
[32]. On the other hand, RXRβ and RARα may form het-
erodimer and control spermiation in vivo because both are
coexpressed in Sertoli cells and invalidation of either gene in
mice leads to similar phenotype [32]. RXRβ-null males are
sterile due to oligoasthenoteratozoospermia caused by failed
spermatid release (from the germinal epithelium) and ab-
normal sperm acrosomes and tails [27]. In Sertoli cells, the
function of RXRβ (coupled with RARα) may involve lipid
metabolism or transport, because they progressively accu-
mulate lipids (which are unsaturated triglycerides) in RXRβ-
null mice. In older RXRβ-null males, germ cells degenerate
completely and seminiferous tubules are filled with lipid vac-
uoles [27]. RARα homozygous mutant [33] and mice with
targeted RARα ablation in Sertoli cells [34] display similar
phenotype. Both have testicular degeneration, failed spermi-
ation, epithelial vacuolation, germ cell desquamation, and
apoptosis [34]. Although there is no report concerning RXR
expression in spermatozoa, it can be inferred that human
sperm express RXR because human sperm express PPARγ
(which forms functional complex with RXR) and PPARγ lig-
and enhances their activities [35].
6.2. RXR in preimplantation embryos
The development of preimplantation embryos was not de-
scribed in the initial reports describing RXRα- [27] and
RXRβ- [28] null mice. However, available information in the
literature shows that preimplantation embryos express RXRs.
Transcripts of RXRα, RXRβ, and RXRγ are expressed in
zebrafish embryos at 1.5 hour postfertilization [36]. RXRα,
RXRβ, and RALDH2 (one of the two enzymes oxidizing
retinol to retinoic acid) are detected in all stages of preim-
plantation bovine embryos, including blastocysts which ex-
press RXRβ protein in the inner cell mass and the trophec-
toderm [30]. RXRα, β, and γ transcripts in preimplanta-
tion bovine embryos are likely of maternal origin because
eight-cell stage and earlier embryos have significantly higher
RXR levels than later stage embryos [37]. Furthermore, RXRs
may be essential for optimal embryo development because
“good-quality” embryos express significantly higher levels of
RXR transcripts than “bad-quality” embryos [37]. It can be
summarized that RXR expression in preimplantation em-
bryos described above is corroborated by the expression of its
partner, PPAR (discussed later). Furthermore, RXR (partners
with PPAR or RAR) is crucial to normal embryo develop-
ment because (1) early stage embryos contain high levels of
maternal RXR mRNA, and (2) “good-quality” embryos ex-
press higher RXR mRNA levels.
7. PPAR IN GAMETES AND PREIMPLANTATION
EMBRYOS
Compared with their role in postimplantation embryo de-
velopment, the roles of PPARs in fertilization, implantation,
and embryo development are less well defined. Available in-
formation does suggest that gametes and preimplantation
embryos express functional PPARs and that PPAR activation
optimizes their functions.
7.1. PPAR and gametes
All three PPAR isotypes are expressed in somatic and germ
cells of the testis. In rat, PPARα and β/δ are expressed in
Leydig cells and Sertoli cells [38]. In human, PPARγ1 mes-
sage is detected in the testis [39]. In mouse, both PPARα
and γ are expressed in Sertoli cells [40], and PPARβ/δ is ex-
pressed in spermatids and spermatocytes [41]. The expres-
sion of PPARβ/δ in mouse spermatids and spermatocytes is
further supported by the expression of Ssm, a novel PPARβ/δ
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target gene, in mouse testis [42]. The functionality of PPARα
in Sertoli cells is confirmed by its nuclear translocation in re-
sponse to a selective PPARα ligand, Wy-14,643 [40]. These
findings suggest that PPARs (in Sertoli cells and Leydig cells)
provide an environment for spermatogenesis and may be di-
rectly involved in germ cell maturation. PPAR may regu-
late germ cell maturation in a stage-dependent fashion. In
zebrafish, PPARγ is expressed in spermatogonia but not in
spermatocytes [43].
PPAR ligand aﬀects spermatogenesis and sperm activi-
ties. Di(n-butyl) phthalate, a PPAR activator, modulates the
expression of genes related to spermatogenesis and steroido-
genesis and causes testicular atrophy in rats [44]. In contrast,
the capacitation, acrosome reaction, and motility of ejacu-
lated human sperm are enhanced by a treatment with rosigli-
tazone (a synthetic PPARγ ligand) or 15d-PGJ2 (a natural
PPARγ ligand) [35]. Since germ cells express all three PPAR
isotypes, the expression and function of two other PPAR iso-
types, PPARα and β/δ, in mature spermatozoa warrant fur-
ther investigation.
In several species including rat, all three PPAR isotypes
are detected in the ovary [2]. PPARγ, which has been stud-
ied more extensively than the other two isotypes, is detected
in the mouse, rat, pig, sheep, cow, and human ovary. PPARγ
is expressed strongly in the granulosa cells of rat [2], mouse
[41], and sheep [45], as well as in oocytes from cattle [30],
zebrafish [43], Xenopus [46], and human [47]. PPARγ is de-
tected in diﬀerent classes of follicles (primary/secondary to
preovulatory follicles) and its expression increases with the
development of follicles. After the LH surge, PPARγ mRNA
expression is downregulated [2]. Activation of PPARγ by nat-
ural and synthetic ligands in the granulosa cells appears to
regulate the synthesis of steroid hormones. Thus, PPARγmay
be indirectly involved in oocyte maturation via the granu-
losa cells. Indeed, disruption of PPARγ gene in the ovary us-
ing cre/loxP technology led to female subfertility [48]. On
the other hand, PPARs may be directly involved in oocyte
maturation. Indeed, it has been reported that rosiglitazone, a
synthetic PPARγ ligand, at 100 μM stimulates AMP-activated
protein kinase (AMPK) and enhances the meiotic resump-
tion of mouse oocytes [42].
7.2. PPAR and preimplantation embryos
Preimplantation bovine and mouse embryos express PPARγ
and PPARβ/δ, respectively. Beginning at two-cell stage and
throughout the preimplantation period, bovine embryos ex-
press PPARγ. Blastocyst stage bovine embryos express PPARγ
in the inner cell mass and the trophectoderm [30]. Mouse
embryos express PPARβ/δ detectable by immunohistochem-
istry at two-cell stage [25] or eight-cell stage [22] and
throughout the preimplantation period. Mouse blastocysts
also express PPARβ/δ in the inner cell mass and the trophec-
toderm [22].
Although preimplantation embryo development and im-
plantation were not specifically examined in the initial re-
port regarding PPARβ/δ-null mouse, the report provides a
hint of the impacts of PPARβ/δ deficiency [49]. The geno-
typic distribution of embryos on gestation day 9.5 shows that
PPARβ/δ−/− embryos are underrepresented: PPARβ/δ−/−
embryos represent 16% (3/19) and 38% (3/8) of embryos
from PPARβ/δ + /− x PPARβ/δ + /− and PPARβ/δ − /− x
PPARβ/δ + /− mating, respectively. This represents a 36%
(i.e., 25% versus 16%) and a 24% (i.e., 50% versus 38%)
deviation from the expected Mendelian frequency. Loss of
PPARβ/δ − /− embryos prior to gestation day 9.5 may oc-
cur at any stage including ovulation, fertilization, preimplan-
tation period, implantation, and postimplantation period
up to gestation day 9.5. The results of our study show that
PPARβ/δ ablation adversely aﬀects preimplantation embryo
development and, consequently, implantation [22]. Com-
pared with wild-type embryos, PPARβ/δ− /− embryos show
developmental delay as early as 48 hours after two-cell stage
embryos are harvested. The gap widens in the subsequent
48 hours. At 96 hours after the harvest of two-cell embryos,
100% of wild-type embryos have reached or passed the blas-
tocyst stage (versus 65% PPARβ/δ − /− embryos), and 85%
of wild-type embryos have undergone hatching or hatched
completely (versus 28% PPARβ/δ − /− embryos). Conse-
quently, PPARβ/δ− /− embryos implant less eﬀectively than
wild-type embryos (28% versus 44%). We also found that
PPARβ/δ−/− embryos have decreased embryonic cell prolif-
eration compared with that observed in wild-type embryos.
These results suggest that PPARβ/δ activation via endoge-
nous PPARβ/δ ligand, such as PGI2 [24] and/or retinoic acid
[18], confers the “basal” momentum (including cell prolifer-
ation and possibly other functions) to preimplantation em-
bryos and propels them through various stages of develop-
ment.
In addition to providing a “basal” momentum of embryo
development via endogenous PPARβ/δ ligand, PPARβ/δ ac-
tivation by synthetic ligand further enhances the develop-
ment and the implantation of cultured embryos. Both L-
165041 (a synthetic PPARβ/δ ligand) and iloprost (a sta-
ble PGI2 analog) enhance complete embryo hatching in a
concentration-dependent manner [22, 50, 51]. Embryos pre-
conditioned with L-165041 or iloprost show higher implan-
tation rates when transferred to gestational carriers [22, 52].
These results suggest that cultured embryos do not reach
their full developmental potential due to insuﬃcient endoge-
nous PPARβ/δ ligands or lack of exogenous PPARβ/δ lig-
ands normally provided by the oviduct. Embryos exposed to
PPARβ/δ ligand have increased embryonic cell proliferation
compared with controlled embryos [22].
8. PPAR AND REPRODUCTIVE TOXICOLOGY
PPAR activators are found in herbicides, industrial plasticiz-
ers (for a brief review see [53]), and personal care products
such as hair spray and solvent for perfumes [54]. Di(n-butyl)
phthalate, a PPARγ activator found in plasticizers and per-
sonal care products, may cause male infertility by altering
hormones involved in steroidogenesis and spermatogenesis
[44]. Other potential PPAR activators posing reproductive
toxicology concerns are pharmaceutical agents used to lower
lipids and blood glucose. Rosiglitazone (a TZD for diabetes)
may activate PPARγ ligand and enhance sperm activities in
men [35] or, depending on its concentration, may enhance
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meiosis resumption of oocytes or induce oocyte degenera-
tion in women [55]. Nonsteroidal anti-inflammatory drugs,
such as Motrin, which blocks PG synthesis, pose reproduc-
tive hazards through a diﬀerent mechanism. Decreased PG
(such as PGI2) production may adversely aﬀect embryo de-
velopment and implantation.
On the other hand, PPARs may be exploited to enhance
the success of assisted reproductive technology. The fertiliza-
tion potentials of human sperm in in vitro fertilization (IVF)
or other assisted reproductive technologies, such as artificial
insemination, may be enhanced by incubating sperm with
synthetic PPARγ ligands. The development and implanta-
tion of IVF embryos may be augmented by supplementing
culture media with PGI2 analogs, synthetic PPARβ/δ ligand,
or retinoic acid. However, potential long-term adverse eﬀects
are unknown. Large-scale clinical trials of suﬃcient power
are needed to validate the benefits and to assess the harms.
9. CONCLUSION
The literature on PPARs in gametes and preimplantation em-
bryos is relatively limited. Nonetheless, the consensus is that
PPAR serves to optimize gamete function and embryo devel-
opment. Further studies are needed to shedmore light on the
physiological roles of PPARs in reproduction. The knowledge
gained will help us avoid potential reproductive hazards and
augment the success of assisted reproductive technologies.
REFERENCES
[1] I. Issemann and S. Green, “Activation of a member of the
steroid hormone receptor superfamily by peroxisome prolif-
erators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.
[2] C. M. Komar, “Peroxisome proliferator-activated receptors
(PPARs) and ovarian function—implications for regulating
steroidogenesis, diﬀerentiation, and tissue remodeling,” Re-
prod Biol Endocrinol, vol. 3, p. 41, 2005.
[3] D. J. Mangelsdorf, C. Thummel, M. Beato, et al., “The nuclear
receptor superfamily: the second decade,” Cell, vol. 83, no. 6,
pp. 835–839, 1995.
[4] F. A. Mic, A. Molotkov, D. M. Benbrook, and G. Duester,
“Retinoid activation of retinoic acid receptor but not retinoid
X receptor is suﬃcient to rescue lethal defect in retinoic acid
synthesis,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 100, no. 12, pp. 7135–7140,
2003.
[5] G. Wolf, “Is 9-cis-retinoic acid the endogenous ligand for the
retinoic acid-X receptor?” Nutrition Reviews, vol. 64, no. 12,
pp. 532–538, 2006.
[6] B. Desvergne and W. Wahli, “Peroxisome proliferator-
activated receptors: nuclear control of metabolism,” Endocrine
Reviews, vol. 20, no. 5, pp. 649–688, 1999.
[7] Y. Shi, M. Hon, and R. M. Evans, “The peroxisome
proliferator-activated receptor δ, an integrator of transcrip-
tional repression and nuclear receptor signaling,” Proceedings
of the National Academy of Sciences of the United States of Amer-
ica, vol. 99, no. 5, pp. 2613–2618, 2002.
[8] S. Kersten, B. Desvergne, and W. Wahli, “Roles of PPARS in
health and disease,” Nature, vol. 405, no. 6785, pp. 421–424,
2000.
[9] N. Di-Poi, N. S. Tan, L. Michalik, W. Wahli, and B. Desvergne,
“Antiapoptotic role of PPARβ in keratinocytes via transcrip-
tional control of the Akt1 signaling pathway,” Molecular Cell,
vol. 10, no. 4, pp. 721–733, 2002.
[10] L. Julan, H. Guan, J. P. van Beek, and K. Yang, “Per-
oxisome proliferator-activated receptor δ suppresses 11β-
hydroxysteroid dehydrogenase type 2 gene expression in hu-
man placental trophoblast cells,” Endocrinology, vol. 146, no. 3,
pp. 1482–1490, 2005.
[11] J.-Y. Liou, S. Lee, D. Ghelani, N. Matijevic-Aleksic, and
K. K. Wu, “Protection of endothelial survival by peroxi-
some proliferator-activated receptor-δ mediated 14-3-3 up-
regulation,” Arteriosclerosis, Thrombosis, and Vascular Biology,
vol. 26, no. 7, pp. 1481–1487, 2006.
[12] H. Lim, R. A. Gupta, W. G. Ma, et al., “Cyclo-oxygenase-
2-derived prostacyclin mediates embryo implantation in the
mouse via PPARδ,” Genes & development, vol. 13, no. 12, pp.
1561–1574, 1999.
[13] R. A. Gupta, D. Wang, S. Katkuri, H. Wang, S. K. Dey, and
R. N. DuBois, “Activation of nuclear hormone receptor per-
oxisome proliferator-activated receptor-δ accelerates intesti-
nal adenoma growth,” Nature Medicine, vol. 10, pp. 245–247,
2004.
[14] R. A. Gupta, J. Tan,W. F. Krause, et al., “Prostacyclin-mediated
activation of peroxisome proliferator-activated receptor δ in
colorectal cancer,” Proceedings of the National Academy of Sci-
ences of the United States of America, vol. 97, no. 24, pp. 13275–
13280, 2000.
[15] N. Di-Poi, L. Michalik, N. S. Tan, B. Desvergne, and W. Wahli,
“The anti-apoptotic role of PPARβ contributes to eﬃcient skin
wound healing,” Journal of Steroid Biochemistry and Molecular
Biology, vol. 85, no. 2–5, pp. 257–265, 2003.
[16] N. Di-Poi, C. Y. Ng, N. S. Tan, et al., “Epithelium-mesenchyme
interactions control the activity of peroxisome proliferator-
activated receptor β/δ during hair follicle development,”
Molecular and Cellular Biology, vol. 25, no. 5, pp. 1696–1712,
2005.
[17] B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic
drugs, polyunsaturated fatty acids, and eicosanoids are ligands
for peroxisome proliferator-activated receptors α and δ,” Pro-
ceedings of the National Academy of Sciences of the United States
of America, vol. 94, pp. 4312–4317, 1997.
[18] T. T. Schug, D. C. Berry, N. S. Shaw, S. N. Travis, and N. Noy,
“Opposing eﬀects of retinoic acid on cell growth result from
alternate activation of two diﬀerent nuclear receptors,” Cell,
vol. 129, no. 4, pp. 723–733, 2007.
[19] K. Hardy and S. Spanos, “Growth factor expression and func-
tion in the human and mouse preimplantation embryo,” Jour-
nal of Endocrinology, vol. 172, no. 2, pp. 221–236, 2002.
[20] J.-C. Huang, F. Arbab, K. J. Tumbusch, J. S. Goldsby, N.
Matijevic-Aleksic, and K. K. Wu, “Human Fallopian tubes ex-
press prostacyclin (PGI) synthase and cyclooxygenases and
synthesize abundant PGI,” Journal of Clinical Endocrinology &
Metabolism, vol. 87, no. 9, pp. 4361–4368, 2002.
[21] J.-C. Huang, J. S. Goldsby, F. Arbab, Z. Melhem, N. Aleksic,
and K. K. Wu, “Oviduct prostacyclin functions as a paracrine
factor to augment the development of embryos,” Human Re-
production, vol. 19, no. 12, pp. 2907–2912, 2004.
[22] J.-C. Huang, W. S. Wun, J. S. Goldsby, I. C. Wun,
D. Noorhasan, and K. K. Wu, “Stimulation of embryo
hatching and implantation by prostacyclin and peroxisome
proliferator-activated receptor δ activation: implication in
IVF,” Human Reproduction, vol. 22, no. 3, pp. 807–814, 2007.
6 PPAR Research
[23] H. Wang, Y. Wen, S. Mooney, B. Behr, and M. L. Polan, “Phos-
pholipase A2 and cyclooxygenase gene expression in human
preimplantation embryos,” Journal of Clinical Endocrinology &
Metabolism, vol. 87, no. 6, pp. 2629–2634, 2002.
[24] J.-C. Huang,W.-S. A.Wun, J. S. Goldsby, N.Matijevic-Aleksic,
and K. K.Wu, “Cyclooxygenase-2-derived endogenous prosta-
cyclin enhances mouse embryo hatching,” Human Reproduc-
tion, vol. 19, no. 12, pp. 2900–2906, 2004.
[25] P. L. Pakrasi and A. K. Jain, “Evaluation of cyclooxygenase 2
derived endogenous prostacyclin in mouse preimplantation
embryo development in vitro,” Life Sciences, vol. 80, no. 16,
pp. 1503–1507, 2007.
[26] W. Krezel, V. Dupe, M Mark, A. Dierich, P. Kastner, and P.
Chambon, “RXR gamma null mice are apparently normal and
compound RXR alpha +/-/RXR beta -/-/RXR gamma -/- mu-
tant mice are viable,” Proceedings of the National Academy of
Sciences of the United states of America, vol. 93, no. 17, pp.
9010–9014, 1996.
[27] P. Kastner, J. M. Grondona, M. Mark, et al., “Genetic anal-
ysis of RXRα developmental function: convergence of RXR
and RAR signaling pathways in heart and eye morphogenesis,”
Cell, vol. 78, no. 6, pp. 987–1003, 1994.
[28] P. Kastner, M. Mark, M. Leid, et al., “Abnormal spermatogen-
esis in RXR β mutant mice,” Genes & development, vol. 10, pp.
80–92, 1996.
[29] M. Mohan, N. R. Thirumalapura, and J. Malayer, “Bovine
cumulus-granulosa cells contain biologically active retinoid
receptors that can respond to retinoic acid,” Reproductive Biol-
ogy and Endocrinology, vol. 1, p. 104, 2003.
[30] M. Mohan, J. R. Malayer, R. D. Geisert, and G. L. Morgan,
“Expression patterns of retinoid X receptors, retinaldehyde de-
hydrogenase, and peroxisome proliferator activated receptor
γ in bovine preattachment embryos,” Biology of Reproduction,
vol. 66, no. 3, pp. 692–700, 2002.
[31] S. Minucci, J. Wong, J. C. G. Blanco, Y.-B. Shi, A. P. Wolﬀe, and
K. Ozato, “Retinoid receptor-induced alteration of the chro-
matin assembled on a ligand-responsive promoter in Xenopus
oocytes,” Molecular Endocrinology, vol. 12, no. 3, pp. 315–324,
1998.
[32] N. Vernet, C. Dennefeld, C. Rochette-Egly, et al., “Retinoic
acid metabolism and signaling pathways in the adult and de-
veloping mouse testis,” Endocrinology, vol. 147, no. 1, pp. 96–
110, 2006.
[33] T. Lufkin, D. Lohnes, M. Mark, et al., “High postnatal lethal-
ity and testis degeneration in retinoic acid receptor α mutant
mice,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 90, pp. 7225–7229, 1993.
[34] N. Vernet, C. Dennefeld, F. Guillou, P. Chambon, N. B. Ghy-
selinck, and M. Mark, “Prepubertal testis development relies
on retinoic acid but not rexinoid receptors in Sertoli cells,”
EMBO Journal, vol. 25, no. 24, pp. 5816–5825, 2006.
[35] S. Aquila, D. Bonofiglio, M. Gentile, et al., “Peroxisome
proliferator-activated receptor (PPAR)γ is expressed by hu-
man spermatozoa: its potential role on the sperm physiology,”
Journal of Cellular Physiology, vol. 209, no. 3, pp. 977–986,
2006.
[36] A. Tallafuss, L. A. Hale, Y.-L. Yan, L. Dudley, J. S. Eisen, and
J. H. Postlethwait, “Characterization of retinoid-X receptor
genes rxra, rxrba, rxrbb and rxrg during zebrafish develop-
ment,” Gene Expression Patterns, vol. 6, no. 5, pp. 556–565,
2006.
[37] S. Mamo, S. Ponsuksili, K. Wimmers, M. Gilles, and K. Schel-
lander, “Expression of retinoid X receptor transcripts and
their significance for developmental competence in in vitro-
produced pre-implantation-stage bovine embryos,” Reproduc-
tion in Domestic Animals, vol. 40, no. 2, pp. 177–183, 2005.
[38] O. Braissant, F. Foufelle, C. Scotto, M. Dauca, and W. Wahli,
“Diﬀerential expression of peroxisome proliferator-activated
receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ
in the adult rat,” Endocrinology, vol. 137, pp. 354–366, 1996.
[39] A. Elbrecht, Y. Chen, C. A. Cullinan, et al., “Molecular cloning,
expression and characterization of human peroxisome prolif-
erator activated receptors γ1 and γ2,” Biochemical and Bio-
physical Research Communications, vol. 224, no. 2, pp. 431–
437, 1996.
[40] N. Bhattacharya, J. M. Dufour, M. N. Vo, J. Okita, R. Okita,
and K. H. Kim, “Diﬀerential eﬀects of phthalates on the testis
and the liver,” Biology of Reproduction, vol. 72, pp. 745–754,
2005.
[41] H. Higashiyama, A. N. Billin, Y. Okamoto, M. Kinoshita, and
S. Asano, “Expression profiling of peroxisome proliferator-
activated receptor-δ (PPAR-δ) in mouse tissues using tissue
microarray,” Histochemistry and Cell Biology, vol. 127, no. 5,
pp. 485–494, 2007.
[42] K. Han, H. Song, I. Moon, et al., “Utilization of DR1 as true
RARE in regulating the Ssm, a novel retinoic acid-target gene
in the mouse testis,” Journal of Endocrinology, vol. 192, pp.
539–551, 2007.
[43] A. Ibabe, M. Grabenbauer, E. Baumgart, H. D. Fahimi, and
M. P. Cajaraville, “Expression of peroxisome proliferator-
activated receptors in zebrafish (Danio rerio),” Histochemistry
and Cell Biology, vol. 118, no. 3, pp. 231–239, 2002.
[44] J. Y. Ryu, B. M. Lee, S. Kacew, and H. S. Kim, “Identification of
diﬀerentially expressed genes in the testis of Sprague-Dawley
rats treated with di(n-butyl) phthalate,” Toxicology, vol. 234,
no. 1-2, pp. 103–112, 2007.
[45] P. Froment, S. Fabre, J. Dupont, et al., “Expression and func-
tional role of peroxisome proliferator-activated receptor-γ in
ovarian folliculogenesis in the sheep,” Biology of Reproduction,
vol. 69, pp. 1665–1674, 2003.
[46] C. Dreyer and H. Ellinger-Ziegelbauer, “Retinoic acid recep-
tors and nuclear orphan receptors in the development of
Xenopus laevis,” International Journal of Developmental Biol-
ogy, vol. 40, no. 1, pp. 255–262, 1996.
[47] J. R. Wood, D. A. Dumesic, D. H. Abbott, and J. F. Strauss III,
“Molecular abnormalities in oocytes from women with poly-
cystic ovary syndrome revealed by microarray analysis,” Jour-
nal of Clinical Endocrinology & Metabolism, vol. 92, no. 2, pp.
705–713, 2007.
[48] Y. Cui, K. Miyoshi, E. Claudio, et al., “Loss of the peroxi-
some proliferation-activated receptor γ (PPARγ) does not af-
fect mammary development and propensity for tumor forma-
tion but leads to reduced fertility,” Journal of Biological Chem-
istry, vol. 277, no. 20, pp. 17830–17835, 2002.
[49] Y. Barak, D. Liao, W. He, et al., “Eﬀects of peroxisome
proliferator-activated receptor δ on placentation, adiposity,
and colorectal cancer,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 99, no. 1, pp. 303–
308, 2002.
[50] J.-C. Huang, W.-S. A. Wun, J. S. Goldsby, I. C. Wun, S. M. Fal-
coni, and K. K. Wu, “Prostacyclin enhances embryo hatching
but not sperm motility,” Human Reproduction, vol. 18, no. 12,
pp. 2582–2589, 2003.
[51] C.-H. Liu, M.-S. Lee, C.-H. Hsieh, C.-C. Huang, H.-M. Tsao,
and Y.-S. Hsieh, “Prostacyclin enhances mouse embryo de-
velopment and hatching but not increased embryonic cell
Jaou-Chen Huang 7
number and volume,” Fertility and Sterility, vol. 86, no. 4, pp.
1047–1052, 2006.
[52] J.-C. Huang, J. S. Goldsby, and W.-S.A. Wun, “Prostacyclin
enhances the implantation and live birth potentials of mouse
embryos,” Human Reproduction, vol. 19, no. 8, pp. 1856–1860,
2004.
[53] E. A. Lock, A. M. Mitchell, and C. R. Elcombe, “Biochemi-
cal mechanisms of induction of hepatic peroxisome prolifera-
tion,” Annual Review of Pharmacology and Toxicology, vol. 29,
pp. 145–163, 1989.
[54] R. H. McKee, J. H. Butala, R. M. David, and G. Gans, “NTP
center for the evaluation of risks to human reproduction re-
ports on phthalates: addressing the data gaps,” Reproductive
Toxicology, vol. 18, no. 1, pp. 1–22, 2004.
[55] J. Chen, E. Hudson, M. M. Chi, et al., “AMPK regulation of
mouse oocyte meiotic resumption in vitro,” Developmental Bi-
ology, vol. 291, no. 2, pp. 227–238, 2006.
